Consigue una respuesta de este empleador — un currículum y una carta de presentación adaptados exactamente a lo que busca para contratar.
Fundación Pública Andaluza Progreso y Salud seeks a researcher to join CABIMER in Seville to advance Type 1 Diabetes therapies using mouse models. The project centers on the role of VDAC1 with in vivo and immunohistological analyses to bridge basic research to clinical impact.
Applicants should hold a University Degree in Science, possess at least two years of mouse research experience, and have authorised animal-handling accreditation and Spain-work documentation.
Organisation/Company Fundación Pública Andaluza Progreso y Salud Research Field Medical sciences » Health sciences Researcher Profile Other Profession Positions Undergraduate Positions Application Deadline 2 Oct 2026 - 23:59 (Europe/Madrid) Country Spain Type of Contract Temporary Job Status Full-time Hours Per Week 35 Is the job funded through the EU Research Framework Programme? Other EU programme Is the Job related to staff position within a Research Infrastructure? No
The Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER) is a pioneering multidisciplinary biomedical research space in Spain, integrating basic and applied research with the aim of translating scientific findings into direct improvements in citizens' health and quality of life. CABIMER is the result of an alliance between the Regional Ministry of Presidency, Health and Emergencies and the Regional Ministry of University, Research and Innovation of the Regional Government of Andalusia (Junta de Andalucía), the State Agency Spanish National Research Council (CSIC), the University of Seville, and the Pablo de Olavide University.
This partnership facilitates the connection between CABIMER researchers, professionals from the Andalusian Public Health System, and the business environment, thereby enhancing the transfer of scientific breakthroughs to clinical practice. Located in the Cartuja Science and Technology Park, CABIMER features a building of over 9,000 m2 equipped with the latest advances in scientific equipment, representing a total investment exceeding €15M. The building houses 20 laboratories and various shared core facilities distributed across three floors, accommodating and enabling the work of approximately 170 research professionals from its constituent institutions.
Dr. Gauthier’s research group focuses on the development of innovative cellular, viral, and pharmacological therapies targeting the root cause of Type 1 Diabetes (T1D) and improving patient health and well-being. To this end, the research projects aim to decipher the fundamental mechanisms promoting the survival and regeneration of islet beta cells, which include cross-talk with the immune system. The long-term objective is the translation of this basic research into the clinic.
Within the group, the project entitled "INVESTIGATING THE ROLE OF VDAC1 IN TYPE 1-DIABETES" is carried out, funded through an ABARCEO collaboration agreement. This project focuses on the preclinical evaluation of novel pharmaceutical compounds for the treatment of type 1 diabetes, combining in vivo studies in murine models with immunological and histological analyses to assess therapeutic efficacy and mechanisms of action.